Trial reportSignal transduction and targeted therapy2026
Coronary atherosclerotic plaque intervention with Tongxinluo capsule (TXL-CAP): a multicenter, randomized, double-blind and placebo-controlled study.
Trial report in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Long Non-Coding RNA in Atherosclerosis: Mechanism and Intervention of Traditional Chinese Medicine.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical evidence of traditional Chinese medicine Tongxinluo capsule therapy on coronary plaque vulnerability is lacking. To investigate whether Tongxinluo may increase coronary plaque stability in patients admitted with acute coronary syndrome based on statin therapy, the TXL-CAP study, a multicenter, randomized, double-blind clinical trial, was conducted. Patients who had a coronary thin-cap lipid-rich plaque detected by optical coherence tomography (OCT) were randomized 1:1 to either Tongxinluo or placebo treatment for 12 months on the basis of guideline-directed treatment. The primary endpoint was the difference in the minimum fibrous cap thickness of the OCT-assessed lesions between Tongxinluo and placebo groups in patients at the end of 12 months. A total of 220 patients were finally recruited and randomized. For the primary endpoint, the minimum fibrous cap thickness did not differ between the two groups at baseline but increased in the Tongxinluo group relative to the placebo group at the 12-month follow-up (115.0 μm vs. 80.0 μm, P < 0.001). The increase in the minimum fibrous cap thickness (61.2 μm vs. 33.7 μm, P = 0.002) and the decrease in the maximum lipid arc (-38.4° vs. -8.1°, P = 0.007) were greater in the Tongxinluo group than in the placebo group. The Tongxinluo group showed improvement in both the Seattle Angina Questionnaire score and the Canadian Cardiovascular Society grading of angina pectoris compared to the placebo group. In conclusion, on the basis of statins, Tongxinluo increased fibrous cap thickness, reduced the lipid arc of coronary thin-cap lipid-rich plaques, and improved angina symptoms without lowering cardiovascular events at the 12-month follow-up in patients with acute coronary syndrome. ( http://www.chictr.org.cn , ID: ChiCTR1900025842).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.